Videos

Joshua Richter, MD, reviews data from two clinical trials investigating selinexor combination therapies for the treatment of multiple myeloma.

Dr Joshua Richter describes the mechanism of action of XPO1 inhibitor selinexor and its use in treating multiple myeloma.

Joshua Richter, MD, gives an overview of relapse/refractory multiple myeloma and the available treatment options.

Carolyn Owen, MD, discusses the phase 3 GLOW study which evaluated fixed-duration ibrutinib and venetoclax in elderly or unfit patients with chronic lymphocytic leukemia. .

Subject matter expert provides a comprehensive overview of available first-line therapy options for patients with unresectable or metastatic melanoma and a BRAF mutation.

Hussein Tawbi, MD, PhD reviews a case study of a 47-year-old woman with BRAF-mutated metastatic melanoma and discusses his approach to workup, including biomarker testing, for patients with the disease.

Erika P. Hamilton, MD, discusses the updated safety analysis of the DESTINY-Breast03 trial and the patients who were enrolled in the study.

David O’Malley, MD, discusses the mechanism of action of ubamatamab as well as findings from a phase 1 trial evaluating the agent in patients with recurrent ovarian cancer.

Emma Searle, PhD, discusses results of the MajestTEC-2 trial combining teclistamab with daratumumab and lenalidomide for patients with multiple myeloma presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

Closing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.

Centering focus on the second-line setting of PD-L1–high metastatic NSCLC, a key opinion leader defines a potential role for chemoimmunotherapy,

Highlighting data from the EMPOWER-Lung1 trial, Marina Chiara Garassino, MD, considers the role of first-line cemiplimab in managing PD-L1–high metastatic NSCLC.

Comprehensive insight to factors that inform the optimal selection of first-line therapy for patients with PD-L1–high metastatic non–small cell lung cancer.

Expert oncologist Marina Chiara Garassino, MD, reflects on a patient case of PD-L1–high metastatic NSCLC and outlines first-line treatment options in this setting.

Jennifer R. Brown, MD, PhD, discusses the mechanism of action of zanubrutinib and how it differs from other Bruton’s tyrosine kinase inhibitors.

Mark R. Litzow, MD, discusses the purpose of a trial of blinatumomab for patients with newly diagnosed B-lineage acute lymphoblastic leukemia.

Tanios Bekaii-Saab, MD, FACP, discusses background that led to the start of the MOUNTAINEER-03 trial.

Benjamin Garmezy, MD, discusses the choice of third-line therapies in patients with advanced renal cell carcinoma.

Dr Peter Voorhees outlines advice for community oncologists who treat patients with R/R multiple myeloma.

Dr Voorhees shares his perspective on bispecifics, ADCs, and CAR T-cell therapy in the treatment landscapes of R/R multiple myeloma.

Dr Peter Voorhees highlights MonumenTAL-1, discussing management of notable adverse events and health-related quality of life outcomes from patients with R/R multiple myeloma.

Dr Peter Voorhees reviews bispecifics under development and updated outcomes data from the MonumenTAL-1 trial, evaluating talquetamab in patients with R/R multiple myeloma.

Peter Voorhees, MD, presents a case of a 63-year-old man with R/R multiple myeloma, shares his initial impressions, and discusses the assessment of clinical relapse in patients with R/R multiple myeloma.

Matthew Ingham, MD, discusses some of the most recent clinical updates in the sarcoma space.

Nathan Pennell, MD, PhD, discusses the importance of developing drugs based on resistance to previous treatments in patients with non–small cell lung cancer.

Thomas Flaig, MD, discusses some of the updated and current NCCN guidelines for patients with bladder cancer.

Cyrus M. Khan, MD, discusses the mechanism of action of glofitamab and its potential use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.

Dr Matthew Galsky contemplates how he would use immunotherapy in patients with MIBC, if it were available for use in both the neoadjuvant and adjuvant setting.

Matthew Galsky, MD, highlights some remaining unmet needs for patients with MIBC, and currently ongoing clinical trials in the neoadjuvant MIBC treatment setting that excite him.

Dr Matthew Galsky explains the adjuvant therapy regimen he would have recommended for the patient with MIBC from the presented case, and whether patient preference factors into his decisions in clinical practice.